(Q34463640)

2 August 2017

1 reference

title

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. (English)

1 reference

2 August 2017

1 reference

1 reference

Senter PD

1

1 reference

2 August 2017

Springer CJ

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Advanced Drug Delivery Reviews

2 August 2017

published in

1 reference

2 August 2017

volume

53

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

247-264

1 reference

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

The emerging role of radioimmunotherapy in haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Monoclonal antibody therapy in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Herceptin (trastuzamab) in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT): a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

A cytotoxic agent can be generated selectively at cancer sites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Development and activities of a new melphalan prodrug designed for tumor-selective activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Site-Specific Prodrug Activation by Antibody-.beta.-Lactamase Conjugates: Preclinical Investigation of the Efficacy and Toxicity of Doxorubicin Delivered by Antibody Directed Catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

A new cephalosporin with a dual mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Prodrug activation via catalytic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Multiple event activation of a generic prodrug trigger by antibody catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900206-X

7 January 2021

10.1016/S0169-409X(01)00206-X

Identifiers

DOI

1 reference

2 August 2017

1 reference